FDA’s review is largely focused on the diagnostic platform itself, which FDA jams into the bucket of being a medical device. The agency is most comfortable when it’s regulating a “contrivance” and not a service or the practice of medicine. So when it comes to diagnostics like the blood testing platform that Theranos developed, FDA focuses mostly on the tools, and not the conduct of the lab, or how the many aspects of a diagnostic service are executed.
Read Full Article »
